Pfizer (PFE) Net Cash Flow (2009 - 2026)

Pfizer has disclosed Net Cash Flow across 18 years of filings, most recently posting $544.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 42.41% year-over-year to $544.0 million; the TTM figure through Mar 2026 stood at $211.0 million (up 121.4% YoY), while the FY2025 annual figure was $49.0 million, up 102.81% from the prior year.
• Net Cash Flow climbed to $544.0 million in Q1 2026, from -$202.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for PFE reached as high as $1.8 billion in Q2 2023 and fell as low as -$2.1 billion in Q1 2024.
• The 5-year median for Net Cash Flow is $173.0 million (2025), against an average of -$66.4 million.
• Annual changes were most pronounced in 2022 — Net Cash Flow jumped 3412.5% — and 2024, when it slumped 405.84%.
• A 5-year view of Net Cash Flow shows it stood at -$507.0 million in 2022, then surged by 38.07% to -$314.0 million in 2023, then plunged by 450.32% to -$1.7 billion in 2024, then jumped by 88.31% to -$202.0 million in 2025, then soared by 369.31% to $544.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $544.0 million, -$202.0 million, and -$304.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.